Bayesian methods for the design and analysis of noninferiority trials

被引:17
|
作者
Gamalo-Siebers, Margaret [1 ]
Gao, Aijun [2 ]
Lakshminarayanan, Mani [3 ]
Liu, Guanghan [4 ]
Natanegara, Fanni [5 ]
Railkar, Radha [3 ]
Schmidli, Heinz [6 ]
Song, Guochen [7 ]
机构
[1] US FDA, Ctr Food Safety & Appl Nutr, College Pk, MD USA
[2] InVent Hlth Clin, Princeton, NJ USA
[3] Pfizer Inc, Biotechnol Clin Dev Stat, Collegeville, PA 19426 USA
[4] Merck Sharp & Dohme Corp, N Wales, PA USA
[5] Eli Lilly & Co, Indianapolis, IN 46285 USA
[6] Novartis Pharma AG, Basel, Switzerland
[7] Quintiles, Durham, NC USA
关键词
Bayesian inference; clinical trial; meta-analysis; noninferiority; ACTIVE-CONTROL TRIALS; SAMPLE-SIZE CALCULATIONS; NON-INFERIORITY TRIALS; CLINICAL-TRIALS; HISTORICAL INFORMATION; STATISTICAL-METHODS; PLACEBO; PROPORTIONS; COMBINATION; HYPOTHESIS;
D O I
10.1080/10543406.2015.1074920
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The gold standard for evaluating treatment efficacy of a medical product is a placebo-controlled trial. However, when the use of placebo is considered to be unethical or impractical, a viable alternative for evaluating treatment efficacy is through a noninferiority (NI) study where a test treatment is compared to an active control treatment. The minimal objective of such a study is to determine whether the test treatment is superior to placebo. An assumption is made that if the active control treatment remains efficacious, as was observed when it was compared against placebo, then a test treatment that has comparable efficacy with the active control, within a certain range, must also be superior to placebo. Because of this assumption, the design, implementation, and analysis of NI trials present challenges for sponsors and regulators. In designing and analyzing NI trials, substantial historical data are often required on the active control treatment and placebo. Bayesian approaches provide a natural framework for synthesizing the historical data in the form of prior distributions that can effectively be used in design and analysis of a NI clinical trial. Despite a flurry of recent research activities in the area of Bayesian approaches in medical product development, there are still substantial gaps in recognition and acceptance of Bayesian approaches in NI trial design and analysis. The Bayesian Scientific Working Group of the Drug Information Association provides a coordinated effort to target the education and implementation issues on Bayesian approaches for NI trials. In this article, we provide a review of both frequentist and Bayesian approaches in NI trials, and elaborate on the implementation for two common Bayesian methods including hierarchical prior method and meta-analytic-predictive approach. Simulations are conducted to investigate the properties of the Bayesian methods, and some real clinical trial examples are presented for illustration.
引用
收藏
页码:823 / 841
页数:19
相关论文
共 50 条
  • [41] Understanding superiority, noninferiority, and equivalence for clinical trials
    Kishore, Kamal
    Mahajan, Rahul
    INDIAN DERMATOLOGY ONLINE JOURNAL, 2020, 11 (06) : 890 - 894
  • [42] Methodological quality of oncology noninferiority clinical trials
    Wayant, Cole
    Ross, Andrew
    Vassar, Matt
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2020, 149
  • [43] New concepts of clinical trials in rheumatoid arthritis: a boom of noninferiority trials
    Landewe, Robert
    van der Heijde, Desiree
    CURRENT OPINION IN RHEUMATOLOGY, 2016, 28 (03) : 316 - 322
  • [44] Bayesian approach to the design and analysis of non-inferiority trials for anti-infective products
    Gamalo, Meg A.
    Tiwari, Ram C.
    LaVange, Lisa M.
    PHARMACEUTICAL STATISTICS, 2014, 13 (01) : 25 - 40
  • [45] The Bayesian Design of Adaptive Clinical Trials
    Giovagnoli, Alessandra
    INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2021, 18 (02) : 1 - 15
  • [46] Assessing the influence of treatment nonadherence on noninferiority trials using the tipping point approach
    Kim, Mimi
    Wang, Cuiling
    Xue, Xiaonan
    STATISTICS IN MEDICINE, 2019, 38 (04) : 650 - 659
  • [47] Noninferiority trials in clinical practice
    Marko, Monika
    Pawliczak, Rafal
    ALERGOLOGIA POLSKA-POLISH JOURNAL OF ALLERGOLOGY, 2019, 6 (04) : 152 - 159
  • [48] The pros and cons of noninferiority trials
    Pocock, SJ
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2003, 17 (04) : 483 - 490
  • [49] Missing Data in Noninferiority Trials
    Wiens, Brian L.
    Rosenkranz, Gerd K.
    STATISTICS IN BIOPHARMACEUTICAL RESEARCH, 2013, 5 (04): : 383 - 393
  • [50] Noninferiority Trials in Interventional Cardiology
    Kolte, Dhaval
    Aronow, Herbert D.
    Abbott, J. Dawn
    CIRCULATION-CARDIOVASCULAR INTERVENTIONS, 2017, 10 (08)